Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.
| Revenue (Most Recent Fiscal Year) | $4.05M |
| Net Income (Most Recent Fiscal Year) | $-50.22M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 29.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1238.52% |
| Net Margin (Trailing 12 Months) | -1238.52% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -79.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.23 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 3.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 32.17M |
| Free Float | 31.51M |
| Market Capitalization | $120.95M |
| Average Volume (Last 20 Days) | 0.23M |
| Beta (Past 60 Months) | 1.52 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.05% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.35% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |